Perinatal risk assessment for patent ductus arteriosus in premature infants.
Data from 2107 inborn premature infants monitored for hemodynamically significant patent ductus arteriosus were used to develop means for clinically assessing at birth the risk of developing patent ductus arteriosus during the first 30 days of life. The overall 30-day incidence rates in birth weight categories 500 to 999, 1000 to 1499 g, and 1500 to 1750 g were 41, 17, and 7%, respectively. At-birth risk estimates obtainable from the derived multivariate functions ranged from 0 to 78% for the 500 to 999 and 1000- to 1499-g categories, and from 0 to 20% for the 1500- to 1750-g category. The derived risk functions provide for enhanced selectivity in the application of measures for the prevention of patent ductus arteriosus.
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D001724:Birth Weight; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis*; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis*; D008423:Maternal Age; D008954:Models, Biological; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D012306:Risk
D006633:Histamine Antagonists; D001241:Aspirin